Ublituximab Significantly Reduces Radiological Disease Activity at 12 Weeks: Post-hoc analysis of Participants with Highly Active Disease in the ULTIMATE I & II Phase 3 Studies

site-sidebar-layout : default
ast-site-content-layout : default
site-content-style : default
site-sidebar-style : default
theme-transparent-header-meta : default
stick-header-meta : default
Drug Category : Array
Conference Category : Array
Lead Author : Robertson D, et. al
Published Date : 17/04/2024
Download Link : https://www.tgtherapeutics.com/wp-content/uploads/2024/04/Radiological-Disease-Activity-AAN-2024-Robertson.pdf
Download Text :
Popup Confirmation? :
astra-migrate-meta-layouts : set
Scroll to Top